COR Stock Analysis: Buy, Sell, or Hold?

COR - Cencora, Inc.

WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
$359.22
7.12 (2.02%) β–²
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 04, 2026 3d

Get Alerted When COR Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

πŸ’‘
Bottom Line:
πŸ’‘ BUY OPPORTUNITY: COR shows positive signals but monitor for confirmation. Market pricing in 1.5% decline. Moderate conviction.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$520.62
Based on 7.2% avg growth
INTRINSIC VALUE TODAY
$323.26
Trading above fair value

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.9x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: COR is currently trading at $359.22, which is considered slightly high relative to its 30-day fair value range of $339.02 to $352.45. The stock's valuation (Forward PE: 18.1) is in line with its historical norms (18.9). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This pessimistic expectation contrasts with the company's recent 45.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, COR is in a strong uptrend. The price is approaching resistance at $362.43. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: COR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $396.47 (+12.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position SLIGHTLY HIGH
Fair Price Range $339.02 - $352.45
Company Quality Score 65/100 (BUY)
Volume Confirmation HIGH
Confidence Score 73.8%

All Signals

  • BULLISH: Strong technical setup (60/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading below Wall St target ($396.47)

Fair Price Analysis

30-Day Fair Range $339.02 - $352.45
Current vs Fair Value SLIGHTLY HIGH

Support & Resistance Levels

Support Level $342.72
Resistance Level $362.43
Current Trend Strong Uptrend

Fundamental Context

Forward P/E (Next Year Est.) 18.12
Wall Street Target $396.47 (+12.6%)
Revenue Growth (YoY) 5.9%
Earnings Growth (YoY) 45.5%
Profit Margin 0.5%
Valuation Discount vs History -1.5% cheaper
PE vs Historical 18.1 vs 18.9 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -1.5% (market-implied from PE analysis)
1-Year Target $346.82 (-2%)
2-Year Target $341.62 (-3%)
3-Year Target $336.49 (-4%)
3-Yr Target (if PE normalizes) (PE: 18β†’19) $351.03 (0%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 22.3, Growth: 10.5%) $584.83 (+66%)
Base: (SPY PE: 18.1, Growth: 10.5%) $475.14 (+35%)
Bear: (PE: 15.4, Growth: 10.5%) $403.87 (+15%)
πŸ“ˆ Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (44x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 44.04 | Current EPS (TTM): $7.96
Bull Case $771.19 (+115%)
Analyst growth 100.0%, PE expands to 48.4
Base Case $701.08 (+95%)
Market implied 100.0%, PE stable at 44.0
Bear Case $238.37 (-34%)
Severe decline -20.0%, PE contracts to 37.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
πŸ’‘ Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.1 to 18.9
Stabilization Target: $367.31 (+4.3%)
PE Expansion Potential: +4.3%
Last updated: January 31, 2026 9:14 AM ET
Data refreshes hourly during market hours. Next update: 10:14 AM
πŸ”₯ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Robert P Mauch SELL 5097 shares 2025-10-20
Robert P Mauch SELL 5097 shares 2025-09-18
Steven H Collis SELL 31350 shares 2025-09-16

Top Rated Medical Distribution Stocks

Top-rated stocks in Medical Distribution by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
MCK
McKesson Corporation
STRONG BUY
17 analysts
$942 60 HOLD
CAH
Cardinal Health Inc
BUY
17 analysts
$230 66 BUY
HSIC
Henry Schein Inc
HOLD
16 analysts
$78 50 HOLD
QIPT
Quipt Home Medical Corp
STRONG BUY
5 analysts
$4 54 HOLD
OMI
Owens & Minor Inc
HOLD
6 analysts
$6 53 HOLD

Advanced COR Option Strategies

Professional options setups generated by AI based on today's COR price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for COR

COR Technical Chart COR Price Prediction COR Earnings Date COR Investment Advisor COR Fair Price Analyzer COR Options Advisor COR Options Chain COR Options Analysis COR Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals